LCI - Lannett gets FDA approval to manufacture Numbrino® at Seymour plant

• The U.S. Food and Drug Administration (FDA) approved micro-cap generic drugmaker Lannett Company ( NYSE: LCI ) to rapidly expand liquid drug manufacturing of Numbrino ^® , the company's branded topical anesthetic product, at its main plant in Seymour, Indiana.
• The company previously manufactured Numbrino and other liquid drug products at its Carmel, New York plant, which it sold in March of this year as part of a restructuring and cost reduction plan.
• NUMBRINO is indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.

For further details see: